South Korea · Delayed Price · Currency is KRW TiumBio Statistics
Total Valuation
TiumBio has a market cap or net worth of KRW 131.27 billion. The enterprise value is 138.36 billion.
| Market Cap | 131.27B |
| Enterprise Value | 138.36B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TiumBio has 30.04 million shares outstanding. The number of shares has increased by 7.45% in one year.
| Current Share Class | 30.04M |
| Shares Outstanding | 30.04M |
| Shares Change (YoY) | +7.45% |
| Shares Change (QoQ) | +3.76% |
| Owned by Insiders (%) | 32.85% |
| Owned by Institutions (%) | n/a |
| Float | 20.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.75 |
| PB Ratio | 2.84 |
| P/TBV Ratio | 3.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.31 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.82 |
| Interest Coverage | -3.14 |
Financial Efficiency
Return on equity (ROE) is -36.65% and return on invested capital (ROIC) is -12.11%.
| Return on Equity (ROE) | -36.65% |
| Return on Assets (ROA) | -10.05% |
| Return on Invested Capital (ROIC) | -12.11% |
| Return on Capital Employed (ROCE) | -27.96% |
| Weighted Average Cost of Capital (WACC) | 3.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.15 |
| Inventory Turnover | 18.02 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.98% in the last 52 weeks. The beta is -0.47, so TiumBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.47 |
| 52-Week Price Change | -17.98% |
| 50-Day Moving Average | 4,210.40 |
| 200-Day Moving Average | 6,673.33 |
| Relative Strength Index (RSI) | 50.10 |
| Average Volume (20 Days) | 91,735 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TiumBio had revenue of KRW 15.00 billion and -17.11 billion in losses. Loss per share was -600.80.
| Revenue | 15.00B |
| Gross Profit | 5.92B |
| Operating Income | -16.08B |
| Pretax Income | -18.40B |
| Net Income | -17.11B |
| EBITDA | -12.54B |
| EBIT | -16.08B |
| Loss Per Share | -600.80 |
Balance Sheet
The company has 32.80 billion in cash and 28.56 billion in debt, with a net cash position of 4.24 billion or 141.11 per share.
| Cash & Cash Equivalents | 32.80B |
| Total Debt | 28.56B |
| Net Cash | 4.24B |
| Net Cash Per Share | 141.11 |
| Equity (Book Value) | 46.27B |
| Book Value Per Share | 1,162.55 |
| Working Capital | 10.55B |
Cash Flow
In the last 12 months, operating cash flow was -14.81 billion and capital expenditures -880.35 million, giving a free cash flow of -15.69 billion.
| Operating Cash Flow | -14.81B |
| Capital Expenditures | -880.35M |
| Depreciation & Amortization | 3.54B |
| Net Borrowing | -4.81B |
| Free Cash Flow | -15.69B |
| FCF Per Share | -522.49 |
Margins
Gross margin is 39.49%, with operating and profit margins of -107.24% and -114.10%.
| Gross Margin | 39.49% |
| Operating Margin | -107.24% |
| Pretax Margin | -122.72% |
| Profit Margin | -114.10% |
| EBITDA Margin | -83.60% |
| EBIT Margin | -107.24% |
| FCF Margin | n/a |
Dividends & Yields
TiumBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.45% |
| Shareholder Yield | -7.45% |
| Earnings Yield | -13.04% |
| FCF Yield | -11.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TiumBio has an Altman Z-Score of 1.62 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.62 |
| Piotroski F-Score | 4 |